Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28068055 | 0.72 | MAOA (0.47) | SCN9AMEN1KMT2AAPAF1TDP2 | |
| SCHEMBL15049168 | 0.72 | KCNN4 (0.34) | — | |
| SCHEMBL15049141 | 0.72 | TNF (0.48) | APAF1TDP2NSD2CASP3PPP1CA | |
| SCHEMBL15049245 | 0.70 | NSD2 (0.47) | APAF1TDP2NSD2CASP3PPP1CA | |
| SCHEMBL29728760 | 0.70 | NSD2 (0.47) | APAF1TDP2NSD2CASP3PPP1CA | |
| SCHEMBL16431495 | 0.68 | APAF1 (0.48) | MEN1KMT2AAPAF1TDP2NSD2 | |
| SCHEMBL9704225 | 0.68 | TRPA1 (0.51) | MEN1KMT2ATNFACHEMAOA | |
| SCHEMBL22325312 | 0.68 | APAF1 (0.45) | MEN1KMT2AAPAF1TDP2NSD2 | |
| SCHEMBL6326557 | 0.67 | APAF1 (0.47) | APAF1TDP2NSD2CASP3PPP1CA | |
| SCHEMBL30853086 | 0.67 | APAF1 (0.47) | APAF1TDP2NSD2CASP3PPP1CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793887-B1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-9150544-B2 | Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-10-06 | — | — | US | disclosed |
| US-20140329801-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2014-11-06 | — | — | US | disclosed |
| EP-2793887-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092756-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2013-06-27 | — | — | WO | disclosed |
| EP-2606893-A1 | Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329801-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | F9, TFPI, SERPINC1 | SCN9A 123/4885MEN1 2117/4885KMT2A 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.